Central Bank of Austria leverages ADVA FSP 3000 for secure high-speed connectivity
25.6.2020 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Central Bank of Austria is deploying its FSP 3000 technology in a new, highly reliable, ultra-secure data center interconnect (DCI) network. With capacity for up to 32Gbit/s Fibre Channel and 100Gbit/s Ethernet services, the infrastructure provides robust, high-speed disaster recovery and business continuity capabilities that are essential for mission-critical operations. It’s protected by ADVA’s ConnectGuard™ Optical encryption and the real-time assurance of the ADVA ALM fiber monitoring solution. ADVA’s open modular FSP 3000 platform ensures that the bank’s redundant point-to-point system is easily scalable and highly efficient with space and power consumption. The network was installed by ADVA’s partners Componet and dacoso, who are also providing ongoing support with maintenance and SLA management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005079/en/
ADVA’s technology is keeping the Central Bank of Austria’s mission-critical data safe and secure (Photo: Business Wire)
“Our customers demand world-class services with unbeatable security and availability. That’s why we’re committed to harnessing the most innovative technology on the market. Built on the ADVA FSP 3000 and secured by ConnectGuard™ Optical encryption, our new DCI network supports the fastest, most advanced SAN connectivity available, ensuring mission-critical data is always accessible and fully protected,” said Daniela Karanitsch, head of IT operations, Central Bank of Austria. “This flexible, high-capacity solution empowers us to tackle huge increases in data demand while also making significant savings on rack space and power consumption. What’s more, its efficiency and sustainability is further enhanced by ADVA’s ALM fiber monitoring technology, which provides round-the-clock visibility and assurance of the entire network.”
The Central Bank of Austria’s new network can transport up to 200Gbit/s on a single wavelength. It supports a wide range of services on one platform, including 1, 10, 25, 40 and 100Gbit/s Ethernet as well as 8, 16 and 32Gbit/s Fibre Channel. That flexibility enables the bank to maximize efficiency as it responds to changing customer requirements. Austria’s most sensitive financial data is now being safeguarded by encryption at the lowest network layer, guaranteeing resilient protection with none of the latency and performance problems that come with other security methods. ADVA’s FSP 3000 ConnectGuard™ Optical was the first encryption solution on the market to support Fibre Channel speeds up to 32Gbit/s. It’s still the only one capable of such speeds to achieve BSI-approved status, enabling its use for EU and NATO restricted data.
“Our FSP 3000 platform gives the Central Bank of Austria exceptionally fast, agile and robust disaster recovery and business continuity capabilities. And with our ALM technology, it delivers precise, real-time insight into the bank’s fiber plant so that any impairments or breaks can be rapidly repaired with minimal disruption. In fact, our ALM has already repaid the bank’s investment by identifying an issue at the service provider end and preventing outages from occurring,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “For a major national bank leasing dark fiber, secure connectivity is of paramount importance. With the low-latency, physical-layer encryption of our FSP 3000 ConnectGuard™, customers throughout Austria can now be sure of a frictionless experience and complete peace of mind when accessing their financial data.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005079/en/
Contact information
For press:
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
+49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
